Neuspera Announces Leadership Expansion with the Addition of New CFO and CMO
San Jose, CA – August 4, 2022 – Neuspera® Medical, a medical device company developing implantable medical device technology for patients battling chronic illness, today announced the hiring of industry veterans Melissa Farina as Chief Financial Officer and Steven Siegel, MD, as Chief Medical Officer. Farina and Siegel have joined Neuspera as the company recently began enrollment of the second phase of their pivotal clinical trial (SANS-UUI). The company presented initial, positive results from the feasibility phase at the American Urologic Association (AUA) 2021 annual meeting and at the winter meeting of the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) in February of this year.
“We are excited to welcome Melissa and Steven to the Neuspera team. Both have exceptional backgrounds, proven leadership ability, and deep domain expertise and will add tremendous value to the company moving forward as we build and scale for clinical and commercial operations,” said Neuspera board member Lori Hu from Vertex Ventures. “Their wealth of knowledge and industry experience will be critical in guiding our strategic plan as we accelerate the pivotal trial and prepare for future milestones.” Farina comes to Neuspera with over 20 years of financial experience in the medical device industry. She has a proven track record of rapid business strategy execution, building high-performance teams, strategic planning, and investor relations. Most recently, Farina served as CFO of the Medical Division of Halma PLC, where she was instrumental in leading group-wide strategy, capital, and resource allocation, as well as merger and acquisition activity to deliver growth and profitability. Prior to that she held several executive leadership positions at LivaNova and Becton Dickinson.
“I look forward to working alongside company management to advance Neuspera’s mission to provide patient-focused solutions for managing chronic illness,” stated Ms. Farina. “I have spent my career delivering on company objectives through rapid execution of critical business financial strategies and am excited to join Neuspera at a time of significant growth.”
Dr. Siegel has been practicing urology for over 35 years and is an internationally recognized expert and pioneer in the evolution of sacral neuromodulation. He participated in multi-center clinical trials with UroSystems in the late 1980s, when he was the Head of the Section of Female Urology and Urodynamics at the Cleveland Clinic. He participated in the pivotal Medtronic trial, which led to InterStim’s original approval for the indication of urinary urge incontinence (UUI) in 1997. He was the national principal Investigator for the Medtronic InSite trial which demonstrated superior success of sacral neuromodulation when compared to standard medical therapy and the durability of sacral neuromodulation out through 5- years of follow-up. Dr. Siegel was the lead author in numerous publications related to the study. He was a founding member of the International Society of Pelvic Neuromodulation, which later merged with the Society of Female Urology and Urodynamics. He has recently retired from his clinical practice and served as the Director of the Minnesota Urology Centers for Female Urology and Continence Care since 1993. “I am very excited to join a pioneering company like Neuspera and its endeavor to provide relief for patients battling the life-limiting symptoms of urinary urgency incontinence,” said Dr. Siegel. “I am passionate about revolutionizing neuromodulation treatment to truly transform how patients and physicians address chronic illness.”
About Neuspera Medical
Neuspera Medical, Inc. is committed to developing implantable medical devices that will improve the lives of patients battling chronic illnesses. The Neuspera platform, which will include the Nuvella system, will provide patients and physicians new, and potentially earlier, treatment options that are less invasive and more adaptable. These therapeutic alternatives aim to help patients restore their health and well-being for a better quality of life.
Investor Relations and Media Contacts:
Chief Financial Officer